Liver growth factor (LGF) is a hepatic mitogen purified some years ago that promotes proliferation of different cell types and the regeneration of damaged tissues, including brain tissue. Considering the possibility that LGF could be used as a therapeutic agent in Parkinson’s disease, we analyzed its potential neuroregenerative and/or neuroprotective activity when peripherally administered to unilaterally 6-hydroxydopamine (6-OHDA)-lesioned rats. For these studies, rats subjected to nigrostriatal lesions were treated intraperitoneally twice a week with LGF (5 microg/rat) for 3 weeks. Animals were sacrificed 4 weeks after the last LGF treatment. The results show that LGF stimulates sprouting of tyrosine hydroxylase-positive terminals and increases tyrosine hydroxylase and dopamine transporter expression, as well as dopamine levels in the denervated striatum of 6-OHDA-lesioned rats. In this structure, LGF activates microglia and raises tumor necrosis factor-alpha protein levels, which have been reported to have a role in neuroregeneration and neuroprotection. Besides, LGF stimulates the phosphorylation of MAPK/ERK1/2 and CREB, and regulates the expression of proteins which are critical for cell survival such as Bcl2 and Akt. Because LGF partially protects dopamine neurons from 6-OHDA neurotoxicity in the substantia nigra, and reduces motor deficits in these animals, we propose LGF as a novel factor that may be useful in the treatment of Parkinson’s disease.
References
[1]
Aron L, Klein R (2011) Repairing the parkinsonian brain with neurotrophic factors. Trends Neurosci 34: 88–100.
[2]
Diaz-Gil JJ, Escartin P, Garcia-Canero R, Trilla C, Veloso JJ, et al. (1986) Purification of a liver DNA-synthesis promoter from plasma of partially hepatectomized rats. Biochem J 235: 49–55.
[3]
Diaz-Gil JJ, Gavilanes JG, Sanchez G, Garcia-Canero R, Garcia-Segura JM, et al. (1987) Identification of a liver growth factor as an albumin-bilirubin complex. Biochem J 243: 443–448.
[4]
Diaz-Gil JJ, Sanchez G, Trilla C, Escartin P (1988) Identification of biliprotein as a liver growth factor. Hepatology 8: 484–486.
[5]
Conde MV, Gonzalez MC, Quintana-Villamandos B, Abderrahim F, Briones AM, et al. (2011) Liver growth factor treatment restores cell-extracellular matrix balance in resistance arteries and improves left ventricular hypertrophy in SHR. Am J Physiol Heart Circ Physiol 301: H1153–1165.
[6]
Diaz Gil JJ, Rua C, Machin C, Cereceda RM, Garcia-Canero R, et al. (1994) Hepatic growth induced by injection of the liver growth factor into normal rats. Growth Regul 4: 113–122.
[7]
Diaz-Gil JJ, Garcia-Monzon C, Rua C, Martin-Sanz P, Cereceda RM, et al. (2009) Liver growth factor antifibrotic activity in vivo is associated with a decrease in activation of hepatic stellate cells. Histol Histopathol 24: 473–479.
[8]
Perez-Crespo M, Pericuesta E, Perez-Cerezales S, Arenas MI, Lobo MV, et al. (2011) Effect of liver growth factor on both testicular regeneration and recovery of spermatogenesis in busulfan-treated mice. Reprod Biol Endocrinol 9: 21.
[9]
Somoza B, Abderrahim F, Gonzalez JM, Conde MV, Arribas SM, et al. (2006) Short-term treatment of spontaneously hypertensive rats with liver growth factor reduces carotid artery fibrosis, improves vascular function, and lowers blood pressure. Cardiovasc Res 69: 764–771.
[10]
Reimers D, Herranz AS, Diaz-Gil JJ, Lobo MV, Paino CL, et al. (2006) Intrastriatal infusion of liver growth factor stimulates dopamine terminal sprouting and partially restores motor function in 6-hydroxydopamine-lesioned rats. J Histochem Cytochem 54: 457–465.
[11]
Gonzalo-Gobernado R, Reimers D, Herranz AS, Diaz-Gil JJ, Osuna C, et al. (2009) Mobilization of neural stem cells and generation of new neurons in 6-OHDA-lesioned rats by intracerebroventricular infusion of liver growth factor. J Histochem Cytochem 57: 491–502.
[12]
Reimers D, Osuna C, Gonzalo-Gobernado R, Herranz AS, Diaz-Gil JJ, et al. (2012) Liver growth factor promotes the survival of grafted neural stem cells in a rat model of Parkinson’s disease. Curr Stem Cell Res Ther 7: 15–25.
[13]
Diaz-Gil JJ, Majano PL, Lopez-Cabrera M, Sanchez-Lopez V, Rua C, et al. (2003) The mitogenic activity of the liver growth factor is mediated by tumor necrosis factor alpha in rat liver. J Hepatol 38: 598–604.
[14]
Suzuki T, Hide I, Ido K, Kohsaka S, Inoue K, et al. (2004) Production and release of neuroprotective tumor necrosis factor by P2X7 receptor-activated microglia. J Neurosci 24: 1–7.
[15]
Wang W, Ji P, Dow KE (2003) Corticotropin-releasing hormone induces proliferation and TNF-alpha release in cultured rat microglia via MAP kinase signalling pathways. J Neurochem 84: 189–195.
[16]
Figiel I (2008) Pro-inflammatory cytokine TNF-alpha as a neuroprotective agent in the brain. Acta Neurobiol Exp (Wars) 68: 526–534.
[17]
Kraft AD, McPherson CA, Harry GJ (2009) Heterogeneity of microglia and TNF signaling as determinants for neuronal death or survival. Neurotoxicology 30: 785–793.
[18]
Schmitt KR, Boato F, Diestel A, Hechler D, Kruglov A, et al. (2010) Hypothermia-induced neurite outgrowth is mediated by tumor necrosis factor-alpha. Brain Pathol 20: 771–779.
[19]
Singh J, Bowers LD (1986) Quantitative fractionation of serum bilirubin species by reversed-phase high-performance liquid chromatography. J Chromatogr 380: 321–330.
[20]
Deumens R, Blokland A, Prickaerts J (2002) Modeling Parkinson’s disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175: 303–317.
[21]
Kirik D, Rosenblad C, Bjorklund A (1998) Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 152: 259–277.
[22]
Paxinos G, Watson C (1997) The Rat Brain in Stereotaxic Coordinates. San Diego: Academic Press.
[23]
Gonzalez-Aparicio R, Flores JA, Fernandez-Espejo E (2010) Antiparkinsonian trophic action of glial cell line-derived neurotrophic factor and transforming growth factor beta1 is enhanced after co-infusion in rats. Exp Neurol 226: 136–147.
[24]
Wree A, Mix E, Hawlitschka A, Antipova V, Witt M, et al. (2011) Intrastriatal botulinum toxin abolishes pathologic rotational behaviour and induces axonal varicosities in the 6-OHDA rat model of Parkinson’s disease. Neurobiol Dis 41: 291–298.
[25]
Monville C, Torres EM, Dunnett SB (2006) Comparison of incremental and accelerating protocols of the rotarod test for the assessment of motor deficits in the 6-OHDA model. J Neurosci Methods 158: 219–223.
[26]
Rozas G, Guerra MJ, Labandeira-Garcia JL (1997) An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Brain Res Protoc 2: 75–84.
[27]
Carlsson A, Lindqvist M (1973) Effect of ethanol on the hydroxylation of tyrosine and tryptophan in rat brain in vivo. J Pharm Pharmacol 25: 437–440.
[28]
Mena MA, Garcia de Yebenes MJ, Tabernero C, Casarejos MJ, Pardo B, et al. (1995) Effects of calcium antagonists on the dopamine system. Clin Neuropharmacol 18: 410–426.
[29]
Frebel K, Wiese S (2006) Signalling molecules essential for neuronal survival and differentiation. Biochem Soc Trans 34: 1287–1290.
[30]
Arthur JS, Fong AL, Dwyer JM, Davare M, Reese E, et al. (2004) Mitogen- and stress-activated protein kinase 1 mediates cAMP response element-binding protein phosphorylation and activation by neurotrophins. J Neurosci 24: 4324–4332.
[31]
Chakrabarty K, Serchov T, Mann SA, Dietzel ID, Heumann R (2007) Enhancement of dopaminergic properties and protection mediated by neuronal activation of Ras in mouse ventral mesencephalic neurones. Eur J Neurosci 25: 1971–1981.
[32]
Sanders EJ, Parker E, Harvey S (2008) Growth hormone-mediated survival of embryonic retinal ganglion cells: signaling mechanisms. Gen Comp Endocrinol 156: 613–621.
[33]
Shah P, Nankova BB, Parab S, La Gamma EF (2006) Short chain fatty acids induce TH gene expression via ERK-dependent phosphorylation of CREB protein. Brain Res 1107: 13–23.
[34]
Zheng WH, Quirion R (2006) Insulin-like growth factor-1 (IGF-1) induces the activation/phosphorylation of Akt kinase and cAMP response element-binding protein (CREB) by activating different signaling pathways in PC12 cells. BMC Neurosci 7: 51.
[35]
Creson TK, Yuan P, Manji HK, Chen G (2009) Evidence for involvement of ERK, PI3K, and RSK in induction of Bcl-2 by valproate. J Mol Neurosci 37: 123–134.
[36]
He F, Wu LX, Shu KX, Liu FY, Yang LJ, et al. (2008) HGF protects cultured cortical neurons against hypoxia/reoxygenation induced cell injury via ERK1/2 and PI-3K/Akt pathways. Colloids Surf B Biointerfaces 61: 290–297.
[37]
Zhang L, Qu Y, Tang J, Chen D, Fu X, et al. (2010) PI3K/Akt signaling pathway is required for neuroprotection of thalidomide on hypoxic-ischemic cortical neurons in vitro. Brain Res 1357: 157–165.
[38]
Afonso-Oramas D, Cruz-Muros I, Alvarez de la Rosa D, Abreu P, Giraldez T, et al. (2009) Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson’s disease. Neurobiol Dis 36: 494–508.
[39]
Liu L, Wang Y, Li B, Jia J, Sun Z, et al. (2009) Evaluation of nigrostriatal damage and its change over weeks in a rat model of Parkinson’s disease: small animal positron emission tomography studies with [(11)C]beta-CFT. Nucl Med Biol 36: 941–947.
[40]
Smith BA, Goldberg NR, Meshul CK (2011) Effects of treadmill exercise on behavioral recovery and neural changes in the substantia nigra and striatum of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri？dine-lesionedmouse. Brain Res 1386: 70–80.
[41]
Cohen AD, Zigmond MJ, Smith AD (2011) Effects of intrastriatal GDNF on the response of dopamine neurons to 6-hydroxydopamine: time course of protection and neurorestoration. Brain Res 1370: 80–88.
[42]
Kirik D, Georgievska B, Rosenblad C, Bjorklund A (2001) Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson’s disease. Eur J Neurosci 13: 1589–1599.
[43]
Yasuhara T, Shingo T, Kobayashi K, Takeuchi A, Yano A, et al. (2004) Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson’s disease. Eur J Neurosci 19: 1494–1504.
[44]
Teismann P, Schulz JB (2004) Cellular pathology of Parkinson’s disease: astrocytes, microglia and inflammation. Cell Tissue Res 318: 149–161.
[45]
Hung SY, Liou HC, Fu WM (2010) The mechanism of heme oxygenase-1 action involved in the enhancement of neurotrophic factor expression. Neuropharmacology 58: 321–329.
[46]
Liang J, Takeuchi H, Jin S, Noda M, Li H, et al. (2010) Glutamate induces neurotrophic factor production from microglia via protein kinase C pathway. Brain Res 1322: 8–23.
[47]
Polazzi E, Contestabile A (2002) Reciprocal interactions between microglia and neurons: from survival to neuropathology. Rev Neurosci 13: 221–242.
[48]
Shein NA, Grigoriadis N, Horowitz M, Umschwief G, Alexandrovich AG, et al. (2008) Microglial involvement in neuroprotection following experimental traumatic brain injury in heat-acclimated mice. Brain Res 1244: 132–141.
[49]
Streit WJ (2002) Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 40: 133–139.
[50]
Yuan H, Zhu X, Zhou S, Chen Q, Ma X, et al. (2010) Role of mast cell activation in inducing microglial cells to release neurotrophin. J Neurosci Res 88: 1348–1354.
Batchelor PE, Liberatore GT, Wong JY, Porritt MJ, Frerichs F, et al. (1999) Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J Neurosci 19: 1708–1716.
[53]
Batchelor PE, Porritt MJ, Martinello P, Parish CL, Liberatore GT, et al. (2002) Macrophages and Microglia Produce Local Trophic Gradients That Stimulate Axonal Sprouting Toward but Not beyond the Wound Edge. Mol Cell Neurosci 21: 436–453.
[54]
Stanic D, Tripanichkul W, Drago J, Finkelstein DI, Horne MK (2004) Glial responses associated with dopaminergic striatal reinnervation following lesions of the rat substantia nigra. Brain Res 1023: 83–91.
[55]
Ling EA, Wong WC (1993) The origin and nature of ramified and amoeboid microglia: a historical review and current concepts. Glia 7: 9–18.
[56]
Chertoff M, Di Paolo N, Schoeneberg A, Depino A, Ferrari C, et al. (2011) Neuroprotective and neurodegenerative effects of the chronic expression of tumor necrosis factor alpha in the nigrostriatal dopaminergic circuit of adult mice. Exp Neurol 227: 237–251.
[57]
Mitchell HM, White DM, Domowicz MS, Kraig RP (2011) Cold pre-conditioning neuroprotection depends on TNF-alpha and is enhanced by blockade of interleukin-11. J Neurochem 117: 187–196.
[58]
Liste I, Garcia-Garcia E, Martinez-Serrano A (2004) The generation of dopaminergic neurons by human neural stem cells is enhanced by Bcl-XL, both in vitro and in vivo. J Neurosci 24: 10786–10795.
[59]
Offen D, Shtaif B, Hadad D, Weizman A, Melamed E, et al. (2001) Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson’s disease. Neurosci Lett 316: 129–132.
[60]
Ziv I, Offen D, Haviv R, Stein R, Panet H, et al. (1997) The proto-oncogene Bcl-2 inhibits cellular toxicity of dopamine: possible implications for Parkinson’s disease. Apoptosis 2: 149–155.
[61]
Barreto GE, Gonzalez J, Torres Y, Morales L (2011) Astrocytic-neuronal crosstalk: implications for neuroprotection from brain injury. Neurosci Res 71: 107–113.
[62]
Shen LH, Li Y, Chopp M (2010) Astrocytic endogenous glial cell derived neurotrophic factor production is enhanced by bone marrow stromal cell transplantation in the ischemic boundary zone after stroke in adult rats. Glia 58: 1074–1081.
[63]
Yan M, Dai H, Ding T, Dai A, Zhang F, et al. (2011) Effects of dexmedetomidine on the release of glial cell line-derived neurotrophic factor from rat astrocyte cells. Neurochem Int 58: 549–557.
[64]
Diaz-Gil JJ, Munoz J, Albillos A, Rua C, Machin C, et al. (1999) Improvement in liver fibrosis, functionality and hemodynamics in CCI4-cirrhotic rats after injection of the Liver Growth Factor. J Hepatol 30: 1065–1072.
[65]
Condezo-Hoyos L, Abderrahim F, Conde MV, Susin C, Diaz-Gil JJ, et al. (2009) Antioxidant activity of liver growth factor, a bilirubin covalently bound to albumin. Free Radic Biol Med 46: 656–662.
[66]
Condezo-Hoyos L, Arribas SM, Abderrahim F, Somoza B, Gil-Ortega M, et al. (2012) Liver growth factor treatment reverses vascular and plasmatic oxidative stress in spontaneously hypertensive rats. J Hypertens 30: 1185–1194.
[67]
Chung YC, Kim SR, Jin BK (2010) Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson’s disease. J Immunol 185: 1230–1237.
[68]
Yang X, Cheng B (2010) Neuroprotective and anti-inflammatory activities of ketogenic diet on MPTP-induced neurotoxicity. J Mol Neurosci 42: 145–153.
[69]
Leinninger GM, Backus C, Uhler MD, Lentz SI, Feldman EL (2004) Phosphatidylinositol 3-kinase and Akt effectors mediate insulin-like growth factor-I neuroprotection in dorsal root ganglia neurons. FASEB J 18: 1544–1546.
[70]
Yu XR, Jia GR, Gao GD, Wang SH, Han Y, et al. (2006) Neuroprotection of insulin against oxidative stress-induced apoptosis in cultured retinal neurons: involvement of phosphoinositide 3-kinase/Akt signal pathway. Acta Biochim Biophys Sin (Shanghai) 38: 241–248.
[71]
Zhu Y, Yang GY, Ahlemeyer B, Pang L, Che XM, et al. (2002) Transforming growth factor-beta 1 increases bad phosphorylation and protects neurons against damage. J Neurosci 22: 3898–3909.
[72]
Zhu ZH, Yang R, Fu X, Wang YQ, Wu GC (2006) Astrocyte-conditioned medium protecting hippocampal neurons in primary cultures against corticosterone-induced damages via PI3-K/Akt signal pathway. Brain Res 1114: 1–10.
[73]
Ralay Ranaivo H, Wainwright MS (2010) Albumin activates astrocytes and microglia through mitogen-activated protein kinase pathways. Brain Res 1313: 222–231.
[74]
Gonzalo-Gobernado R, Calatrava-Ferreras L, Casarejos MJ, Reimers D, Herranz AS, et al.. (2011) La glía como mediadora del efecto neurotrófico del factor de crecimiento de hígado (LGF) en las neuronas dopaminérgicas da？adas: estudios in Vitro. XIV Congreso Nacional de la Sociedad Espa？ola de Neurociencia.
[75]
Lu J, Wu DM, Hu B, Zheng YL, Zhang ZF, et al. (2010) NGF-Dependent activation of TrkA pathway: A mechanism for the neuroprotective effect of troxerutin in D-galactose-treated mice. Brain Pathol 20: 952–965.
[76]
Milligan SA, Owens MW, Grisham MB (1998) Differential regulation of extracellular signal-regulated kinase and nuclear factor-kappa B signal transduction pathways by hydrogen peroxide and tumor necrosis factor. Arch Biochem Biophys 352: 255–262.
[77]
Noshita N, Lewen A, Sugawara T, Chan PH (2001) Evidence of phosphorylation of Akt and neuronal survival after transient focal cerebral ischemia in mice. J Cereb Blood Flow Metab 21: 1442–1450.
[78]
Zhao H, Sapolsky RM, Steinberg GK (2006) Phosphoinositide-3-kinase/akt survival signal pathways are implicated in neuronal survival after stroke. Mol Neurobiol 34: 249–270.
[79]
Matsuzaki H, Tamatani M, Mitsuda N, Namikawa K, Kiyama H, et al. (1999) Activation of Akt kinase inhibits apoptosis and changes in Bcl-2 and Bax expression induced by nitric oxide in primary hippocampal neurons. J Neurochem 73: 2037–2046.
[80]
Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, et al. (2000) MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 79: 355–369.
[81]
Barneda-Zahonero B, Minano-Molina A, Badiola N, Fado R, Xifro X, et al. (2009) Bone morphogenetic protein-6 promotes cerebellar granule neurons survival by activation of the MEK/ERK/CREB pathway. Mol Biol Cell 20: 5051–5063.
[82]
Herold S, Jagasia R, Merz K, Wassmer K, Lie DC (2011) CREB signalling regulates early survival, neuronal gene expression and morphological development in adult subventricular zone neurogenesis. Mol Cell Neurosci 46: 79–88.
[83]
Lee HT, Chang YC, Tu YF, Huang CC (2010) CREB activation mediates VEGF-A’s protection of neurons and cerebral vascular endothelial cells. J Neurochem 113: 79–91.
[84]
Lin E, Cavanaugh JE, Leak RK, Perez RG, Zigmond MJ (2008) Rapid activation of ERK by 6-hydroxydopamine promotes survival of dopaminergic cells. J Neurosci Res 86: 108–117.
[85]
Fujino H, Kitaoka Y, Hayashi Y, Munemasa Y, Takeda H, et al. (2009) Axonal protection by brain-derived neurotrophic factor associated with CREB phosphorylation in tumor necrosis factor-alpha-induced optic nerve degeneration. Acta Neuropathol 117: 75–84.
[86]
Hannila SS, Filbin MT (2008) The role of cyclic AMP signaling in promoting axonal regeneration after spinal cord injury. Exp Neurol 209: 321–332.
[87]
Teng FY, Tang BL (2006) Axonal regeneration in adult CNS neurons–signaling molecules and pathways. J Neurochem 96: 1501–1508.
[88]
Lewis-Tuffin LJ, Quinn PG, Chikaraishi DM (2004) Tyrosine hydroxylase transcription depends primarily on cAMP response element activity, regardless of the type of inducing stimulus. Mol Cell Neurosci 25: 536–547.
[89]
Lim J, Yang C, Hong SJ, Kim KS (2000) Regulation of tyrosine hydroxylase gene transcription by the cAMP-signaling pathway: involvement of multiple transcription factors. Mol Cell Biochem 212: 51–60.
[90]
Watson F, Kiernan RS, Deavall DG, Varro A, Dimaline R (2001) Transcriptional activation of the rat vesicular monoamine transporter 2 promoter in gastric epithelial cells: regulation by gastrin. J Biol Chem 276: 7661–7671.
[91]
Mehta D, Malik AB (2006) Signaling mechanisms regulating endothelial permeability. Physiol Rev 86: 279–367.
[92]
Predescu D, Vogel SM, Malik AB (2004) Functional and morphological studies of protein transcytosis in continuous endothelia. Am J Physiol Lung Cell Mol Physiol 287: L895–901.
[93]
Sagare AP, Winkler EA, Bell RD, Deane R, Zlokovic BV (2011) From the liver to the blood-brain barrier: an interconnected system regulating brain amyloid-beta levels. J Neurosci Res 89: 967–968.
[94]
Thornalley PJ (1998) Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol (Noisy-le-grand) 44: 1013–1023.
[95]
Park IH, Yeon SI, Youn JH, Choi JE, Sasaki N, et al. (2004) Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol Immunol 40: 1203–1211.
[96]
Wang Z, Li DD, Liang YY, Wang DS, Cai NS (2002) Activation of astrocytes by advanced glycation end products: cytokines induction and nitric oxide release. Acta Pharmacol Sin 23: 974–980.
